Effectiveness of Amantadine Hydrochloride for Treatment of Severe Traumatic Brain Injury (TBI)
Study Details
Study Description
Brief Summary
This is a controlled trial of amantadine to improve level of function following severe traumatic brain injury.
The purpose of this study is:
-
To determine whether amantadine hydrochloride, given in a dose of 200-400 mg, improves functional recovery from the vegetative and minimally conscious states
-
To determine whether amantadine-related gains in function persist following drug discontinuation
-
To determine the safety profile of amantadine in patients with disorders of consciousness
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2/Phase 3 |
Detailed Description
Severe traumatic brain injury may result in severe disorders of consciousness (DOC), including coma, the vegetative state (VS) and the minimally conscious state (MCS). The longer the duration of impaired consciousness, the worse the ultimate functional prognosis, with only about half of those individuals who remain unconscious for a month post-TBI regaining consciousness within a year. The severe functional disability associated with prolonged DOC places enormous emotional, financial, ethical, and logistical strains on caregivers and major resource demands on society. Numerous treatments have been recommended to hasten the return of consciousness or improve the ultimate level of recovery, including various psychotropic drugs, "coma stimulation" therapy and others. However, none of these treatments has proven efficacy in well-controlled research. The main obstacles to Class I evidence in this area have been the small samples of individuals with serious DOC in individual facilities, the variability of recovery trajectories within this heterogeneous population, and the reluctance to undertake placebo controlled trials.
In the proposed study, 7 facilities (including two with TBI Model Systems designations) that participated in a multi-center research network called the Consciousness Consortium, join with four additional brain injury rehabilitation centers (two in the U.S. and two in Europe) and a Data Coordinating Center at Columbia University, to conduct a prospective double blind randomized controlled trial of amantadine hydrochloride. 184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) vs. placebo, followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure. We hypothesize superior recovery in the amantadine group and maintenance of that advantage after washout. We will also explore whether treatment response differs by time post-injury and by diagnosis (i.e., VS or MCS) at treatment onset, and whether specific outcomes of importance to caregivers are achieved more often in the amantadine group. We have developed plans for intensive education of caregivers and clinicians about this study to address perceived barriers to enrollment and will also use the information gathered during these interactions to develop consumer-oriented dissemination activities. Project outputs and findings will be disseminated to appropriate consumer and professional audiences using a variety of formats and will include: (1) improved family member understanding of DOC which will facilitate improved adjustment and caregiving and (2) clear guidance to clinicians regarding the effectiveness of amantadine for persons with DOC.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Amantadine HCL 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4. |
Drug: Amantadine Hydrochloride
184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
Other Names:
|
| Placebo Comparator: Placebo
|
Drug: Placebo
Placebo administered twice daily.
|
Outcome Measures
Primary Outcome Measures
- Disability Rating Scale: Functional Status [Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6.]
Measure of function after traumatic brain injury (TBI) intended to measure function from "coma to community." Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability).
Secondary Outcome Measures
- JFK Coma Recovery Scale-Revised: Neurobehavioral Status [Week 4 (primary endpoint); Week 6 (post-washout)]
Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness. Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function).
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Individuals between ages 16 and 65 with traumatic brain injury as defined by the TBI Model System syllabus (i.e., damage to brain tissue caused by an external mechanical force as evidenced by loss of consciousness or post-traumatic amnesia due to brain trauma, skull fracture, or objective neurological findings that can be reasonably attributed to TBI on physical or mental status examination).
-
Individuals are at least 4 weeks but less than 16 weeks post-injury and have a Disability Rating Scale (DRS) score at enrollment of 12 or greater, and no consistent command following or functional communication (as defined by the JFK.
Exclusion Criteria:
-
Women who are pregnant,
-
Individuals with missile-type penetrating brain injury,
-
Premorbid major CNS/developmental abnormality (e.g., mental retardation, prior significant brain damage, etc.),
-
History of more than 1 seizure (clinical or electrographic, but not including epileptiform or other irritative discharges) in the 4 weeks prior to enrollment (individuals with premorbid idiopathic epilepsy are eligible to enroll under two conditions: a) if their pre-injury seizure frequency was less than once/month and they have had no more than 1 seizure/month since injury and b) if a clear provocation was present that would otherwise disqualify a subject, the subject can be enrolled, since these events would not be considered idiopathic),
-
Prior exposure to AH post-TBI,
-
Unwillingness to discontinue or change confounding psychotropic drugs prior to enrollment, OR
-
Allergy or medical contraindication to AH and significant impairment of renal function (as evidenced by a calculated creatinine clearance of < 60 ml/min).
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Braintree Rehabilitation Hospital | Braintree | Massachusetts | United States | 02184 |
| 2 | Methodist Rehabilitation Center | Jackson | Mississippi | United States | 39216 |
| 3 | Columbia University | New York | New York | United States | 10032 |
| 4 | Sunnyview Rehabilitation Hospital | Schenectady | New York | United States | 12308 |
| 5 | Charlotte Rehabilitation Center | Charlotte | North Carolina | United States | 28203 |
| 6 | Moss Rehabilitation Research Institute | Elkins Park | Pennsylvania | United States | 19027 |
| 7 | Bryn Mawr Rehabilitation Hospital | Malvern | Pennsylvania | United States | 19355 |
| 8 | Texas NeuroRehabilitation Center | Austin | Texas | United States | 78745 |
| 9 | Hvidovre University Hospital | Hvidovre | Denmark | DK 2650 | |
| 10 | Neurologische Klinik Bad Aibling | Bad Aibling | Germany | 83043 | |
| 11 | Fachkrankenhaus Neresheim | Neresheim | Germany | 73450 |
Sponsors and Collaborators
- JFK Medical Center
- U.S. Department of Education
Investigators
- Principal Investigator: Joseph T. Giacino, Ph.D., Spaulding Rehabilitation Hospital
- Principal Investigator: John Whyte, MD, Ph.D., Moss Rehabilitation Research Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- H133A031713
Study Results
Participant Flow
| Recruitment Details | February 23,2003 through March 15, 2010. Eleven rehabilitations centers in the USA (8) and Europe (3) |
|---|---|
| Pre-assignment Detail |
| Arm/Group Title | Amantadine HCL | Placebo |
|---|---|---|
| Arm/Group Description | 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4. | Visually identical compound administered in the same manner (ie enterally) as the actual study drug. |
| Period Title: Overall Study | ||
| STARTED | 87 | 97 |
| COMPLETED | 86 | 95 |
| NOT COMPLETED | 1 | 2 |
Baseline Characteristics
| Arm/Group Title | Amantadine HCL | Placebo | Total |
|---|---|---|---|
| Arm/Group Description | 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4. | Visually identical compound administered in the same manner (ie enterally) as the actual study drug. | Total of all reporting groups |
| Overall Participants | 87 | 97 | 184 |
| Age (Count of Participants) | |||
| <=18 years |
5
5.7%
|
1
1%
|
6
3.3%
|
| Between 18 and 65 years |
82
94.3%
|
96
99%
|
178
96.7%
|
| >=65 years |
0
0%
|
0
0%
|
0
0%
|
| Age (years) [Mean (Standard Deviation) ] | |||
| Mean (Standard Deviation) [years] |
35.5
(15.3)
|
37.2
(15.4)
|
36.4
(15.4)
|
| Sex: Female, Male (Count of Participants) | |||
| Female |
23
26.4%
|
28
28.9%
|
51
27.7%
|
| Male |
64
73.6%
|
69
71.1%
|
133
72.3%
|
| Region of Enrollment (participants) [Number] | |||
| United States |
61
70.1%
|
73
75.3%
|
134
72.8%
|
| Denmark |
3
3.4%
|
2
2.1%
|
5
2.7%
|
| Germany |
23
26.4%
|
22
22.7%
|
45
24.5%
|
Outcome Measures
| Title | JFK Coma Recovery Scale-Revised: Neurobehavioral Status |
|---|---|
| Description | Measure of neurobehavioral function and clinical change for individuals with severe alterations of consciousness. Minimum score= 0; Maximum score= 23 (Higher scores are indicative of a higher-level of neurobehavioral function). |
| Time Frame | Week 4 (primary endpoint); Week 6 (post-washout) |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analyses were conducted according to the ITT principle so that all 184 patients randomized were included for analysis. Imputation techniques were not undertaken since missing data were infrequent and unrelated to study outcome. |
| Arm/Group Title | Amantadine | Placebo |
|---|---|---|
| Arm/Group Description | Amantadine (200-400 mg/day) | Visually identical compound administered in the same manner (ie enterally) as the study drug. |
| Measure Participants | 87 | 97 |
| Week 4 (Primary endpoint) |
15.8
(6.1)
|
14.2
(6.6)
|
| Week 6 (Post-washout) |
15.7
(6.3)
|
15.1
(6.8)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Amantadine, Placebo |
|---|---|---|
| Comments | We will have 80% power to detect a one point difference in DRS score between the groups across the four week treatment window. With this sample size, we will be able to detect any unforeseen adverse events that have a prevalence of at least 2.5% in each group with 90% probability. With 92 patients per group we will be able to estimate the rate of adverse events to within ±10%. | |
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.045 |
| Comments | ||
| Method | Mixed Models Analysis | |
| Comments | ||
| Title | Disability Rating Scale: Functional Status |
|---|---|
| Description | Measure of function after traumatic brain injury (TBI) intended to measure function from "coma to community." Minimum score= 0; Maximum score= 29 (High scores are indicative of greater degree of disability). |
| Time Frame | Randomization and weekly for 6 weeks. The primary study endpoint was week 4 and drug washout was week 6. |
Outcome Measure Data
| Analysis Population Description |
|---|
| Analyses were conducted according to the intention-to-treat principle. 184 subjects were randomized and included for analysis. Since missing data were infrequent and unrelated to the study outcome, imputation methods were not undertaken. |
| Arm/Group Title | Amantadine | Placebo |
|---|---|---|
| Arm/Group Description | Amantadine (200-400 mg/day) | Visually identical compound administered in the same manner (ie enterally) as the actual study drug. |
| Measure Participants | 87 | 97 |
| Week 4 (Primary endpoint) |
17.3
(4.7)
|
18.7
(4.5)
|
| Week 6 (Drug washout) |
17.1
(5.2)
|
17.8
(5.3)
|
Statistical Analysis 1
| Statistical Analysis Overview | Comparison Group Selection | Amantadine, Placebo |
|---|---|---|
| Comments | The planned sample size of 184 patients provided 80% power to detect a difference between the AH and placebo in the rate of Disability Rating Scale (DRS) score change of 0.3 points/week (1.22 DRS point mean difference by the end of the 4-week treatment interval). Two blinded interim analyses were conducted at 60 and 120 patients recruited using the O'Brien-Fleming boundary, with alpha levels of 0.0005 and 0.014. The final analysis used an alpha level of 0.045. | |
| Type of Statistical Test | Superiority or Other | |
| Comments | ||
| Statistical Test of Hypothesis | p-Value | 0.007 |
| Comments | The final analysis used a significance level of 0.045. | |
| Method | Mixed Models Analysis | |
| Comments | Final analysis adjusted for early v. late enrollment relative to date of injury, baseline CRS-R rating category (MCS vs. VS), and site. | |
| Method of Estimation | Estimation Parameter | Slope |
| Estimated Value | -0.24 | |
| Confidence Interval |
() 95% -0.41 to -0.07 |
|
| Parameter Dispersion |
Type: Standard Error of the Mean Value: 0.088 |
|
| Estimation Comments | ||
Adverse Events
| Time Frame | ||||
|---|---|---|---|---|
| Adverse Event Reporting Description | ||||
| Arm/Group Title | Amantadine HCL | Placebo | ||
| Arm/Group Description | 100mg BID administered for 2 weeks, then increased to 150mg BID in week 3 if change on primary outcome measure (ie Disability Rating Scale, DRS) was less than 2 points after week 2. If change in DRS score remained less than 2 points after week 3, dose was increased to 200mg BID in week 4. | Visually identical compound administered in the same manner (ie enterally) as the actual study drug. | ||
All Cause Mortality |
||||
| Amantadine HCL | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | / (NaN) | / (NaN) | ||
Serious Adverse Events |
||||
| Amantadine HCL | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 15/87 (17.2%) | 19/97 (19.6%) | ||
| Blood and lymphatic system disorders | ||||
| Leukocytosis | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Other Abnormal Laboratory | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Cardiac disorders | ||||
| Cardiac arrest | 1/87 (1.1%) | 1 | 0/97 (0%) | 0 |
| Gastrointestinal disorders | ||||
| Other Gastrointestinal Problems | 2/87 (2.3%) | 2 | 3/97 (3.1%) | 3 |
| General disorders | ||||
| General Medical Problems | 1/87 (1.1%) | 1 | 2/97 (2.1%) | 2 |
| Vomiting | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Infections and infestations | ||||
| Infection | 3/87 (3.4%) | 3 | 5/97 (5.2%) | 5 |
| Nervous system disorders | ||||
| Epilepsy | 0/87 (0%) | 0 | 2/97 (2.1%) | 2 |
| Hydrocephalus | 3/87 (3.4%) | 3 | 2/97 (2.1%) | 2 |
| Intracranial Hemorrage | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Other Neurologic | 1/87 (1.1%) | 1 | 1/97 (1%) | 1 |
| Autonomic Storm | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Psychiatric disorders | ||||
| Hypoarousal/Lethargy/Somnolence | 0/87 (0%) | 0 | 1/97 (1%) | 1 |
| Renal and urinary disorders | ||||
| Urinary tract infection | 1/87 (1.1%) | 1 | 0/97 (0%) | 0 |
| Respiratory, thoracic and mediastinal disorders | ||||
| Pneumonia | 6/87 (6.9%) | 6 | 2/97 (2.1%) | 2 |
Other (Not Including Serious) Adverse Events |
||||
| Amantadine HCL | Placebo | |||
| Affected / at Risk (%) | # Events | Affected / at Risk (%) | # Events | |
| Total | 54/87 (62.1%) | 51/97 (52.6%) | ||
| General disorders | ||||
| Insomnia / Sleep Disturbance | 12/87 (13.8%) | 14 | 14/97 (14.4%) | 15 |
| General Medical Problems | 9/87 (10.3%) | 10 | 11/97 (11.3%) | 16 |
| Infections and infestations | ||||
| Infections | 10/87 (11.5%) | 14 | 15/97 (15.5%) | 16 |
| Musculoskeletal and connective tissue disorders | ||||
| Hypertonia / Spasticity | 18/87 (20.7%) | 21 | 14/97 (14.4%) | 18 |
| Psychiatric disorders | ||||
| Agitation / Aggression | 12/87 (13.8%) | 16 | 11/97 (11.3%) | 14 |
| Renal and urinary disorders | ||||
| Urinary tract infection | 13/87 (14.9%) | 15 | 12/97 (12.4%) | 13 |
Limitations/Caveats
More Information
Certain Agreements
Principal Investigators are NOT employed by the organization sponsoring the study.
The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
Results Point of Contact
| Name/Title | Joseph T Giacino, PhD |
|---|---|
| Organization | Spaulding Rehabilitation Hospital |
| Phone | 617-573-2757 |
| jgiacino@partners.org |
- H133A031713